ondansetron has been researched along with Intestinal Diseases in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, S | 1 |
| Matsuda, N | 1 |
| Matsumoto, K | 1 |
| Wada, M | 1 |
| Onimaru, N | 1 |
| Yasuda, M | 1 |
| Amagase, K | 1 |
| Horie, S | 1 |
| Takeuchi, K | 1 |
1 other study available for ondansetron and Intestinal Diseases
| Article | Year |
|---|---|
Dual role of serotonin in the pathogenesis of indomethacin-induced small intestinal ulceration: pro-ulcerogenic action via 5-HT3 receptors and anti-ulcerogenic action via 5-HT4 receptors.
Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Ulcer Agents; Benzamides; Fencloni | 2012 |